Linked Life Data

21247062

Source:http://linkedlifedata.com/resource/pubmed/id/21247062

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2011-1-20
pubmed:abstractText
Due to the high homology between the LAGE-1 and NY-ESO-1 proteins, we hypothesized that an anti-NY-ESO-1 vaccine might elicit LAGE-1 immunity and hence may be effective in multiple myeloma (MM) patients with LAGE-1-positive/NY-ESO-1-negative tumors. Therefore, we set out to evaluate LAGE-1 and NY-ESO-1 mRNA and protein expression in MM patients in a bid to evaluate possible benefits of their homology for immunotherapy. LAGE-1 (a and b isoforms) and NY-ESO-1 mRNA expression was studied in 18 normal tissues and 50 bone marrow MM samples by RT-PCR. LAGE-1 and NY-ESO-1 protein expression was analyzed by immunohistochemistry (IHC) in 27 MM specimens using mAbs 219-510-23 and E978. Spontaneous serological immune response against both antigens was analyzed by ELISA in sera from 33 MM patients. LAGE-1 (a and b isoforms) was positive in 42% and NY-ESO-1 in 26% of the MM samples analyzed by RT-PCR. Both genes were found to be expressed in 18% of the cases, while at least one of the genes was found to be expressed in 50% of the cases. In LAGE-1 positive samples, 81% were positive for LAGE-1a and 19% were positive for both LAGE-1a and -1b. LAGE-1 and NY-ESO-1 protein expression could only be detected in two cases by IHC and there was a clear strong spontaneous antibody response to LAGE-1 and NY-ESO-1 in only one MM patient. In conclusion, LAGE-1a and NY-ESO-1 homology cannot be easily exploited in an anti-NY-ESO-1 vaccine given the low frequency of protein expression detected by IHC or serum analysis.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/21247062-11351307, http://linkedlifedata.com/resource/pubmed/commentcorrection/21247062-12190937, http://linkedlifedata.com/resource/pubmed/commentcorrection/21247062-15026363, http://linkedlifedata.com/resource/pubmed/commentcorrection/21247062-15623618, http://linkedlifedata.com/resource/pubmed/commentcorrection/21247062-15761016, http://linkedlifedata.com/resource/pubmed/commentcorrection/21247062-15809451, http://linkedlifedata.com/resource/pubmed/commentcorrection/21247062-16432832, http://linkedlifedata.com/resource/pubmed/commentcorrection/21247062-16751374, http://linkedlifedata.com/resource/pubmed/commentcorrection/21247062-17023585, http://linkedlifedata.com/resource/pubmed/commentcorrection/21247062-1757079, http://linkedlifedata.com/resource/pubmed/commentcorrection/21247062-18237105, http://linkedlifedata.com/resource/pubmed/commentcorrection/21247062-18323799, http://linkedlifedata.com/resource/pubmed/commentcorrection/21247062-18426187, http://linkedlifedata.com/resource/pubmed/commentcorrection/21247062-19088187, http://linkedlifedata.com/resource/pubmed/commentcorrection/21247062-19381944, http://linkedlifedata.com/resource/pubmed/commentcorrection/21247062-9626360
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1424-9634
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1
pubmed:dateRevised
2011-7-28
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
Evaluation of LAGE-1 and NY-ESO-1 expression in multiple myeloma patients to explore possible benefits of their homology for immunotherapy.
pubmed:affiliation
Disciplina de Hematologia e Hemoterapia, Universidade Federal de São Paulo, São Paulo, Brazil.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't